Core Viewpoint - The company held an online investor meeting on September 19, 2025, to discuss performance and new products, indicating a proactive approach to investor relations [1][2]. Performance and Strategy - In Q2 2025, the company's net profit attributable to shareholders was 19.35 million, a decrease from 22.94 million in Q1 2025, attributed to external macroeconomic factors such as U.S. tariffs [3]. - The company aims to achieve a net profit target of 80 million for the year through market expansion, product optimization, cost reduction, and detailed management strategies [3]. New Product Highlights - The upcoming smart ring will feature standard monitoring functions like blood oxygen, sleep, and heart rate, along with cardiovascular monitoring capabilities [4]. - The sales strategy includes leveraging the company's brand in the domestic market and focusing on large clients and remote patient monitoring (RPM) in international markets [4]. Cardiovascular AI Model Progress - The cardiovascular AI model is a key component of the company's health management services, utilizing wearable devices to collect physiological data for real-time analysis and intervention [5]. Stock Price and Operational Status - The company reassured that its operations are normal despite stock price fluctuations, which are influenced by multiple factors [6]. - In the first half of 2025, the company reported a net profit of 42.29 million, a year-on-year increase of 21.35%, and has implemented a semi-annual dividend [6]. Management Changes - Recent management adjustments are aimed at aligning with the latest strategic goals, with key personnel bringing valuable experience to enhance operational efficiency [7][8]. Market Value Aspirations - The management is focused on creating long-term value for shareholders and aims to enhance its position as a leading provider of medical monitoring devices, although specific plans for achieving a market value of 100 billion have not been disclosed [9].

Financial Performance - In Q2 2025, the company's net profit attributable to shareholders was CNY 19.35 million, a decrease from CNY 22.94 million in Q1 2025, primarily due to external macroeconomic factors [1] - For the first half of 2025, the net profit reached CNY 42.29 million, representing a year-on-year growth of 21.35% [2] - The company aims to achieve a full-year net profit target of CNY 80 million through various strategic measures [2] Product Development - The company’s smart ring has completed hardware development and passed consumer certification, with major clients already receiving samples [2] - The smart ring will offer advanced monitoring features beyond typical products, including cardiovascular status assessment [3] - The cardiovascular AI model has been developed to provide real-time health monitoring and intervention plans [3] Management and Strategy - Recent management changes are aimed at aligning with the latest strategic goals, enhancing operational efficiency [4] - The company has seen a significant turnaround in profitability, moving from a net loss of CNY 32.36 million in 2022 to a profit of CNY 34.37 million in 2023, and CNY 61.36 million in 2024 [5] - The management is focused on long-term value creation and aims to enhance the company's market position through strategic upgrades and innovation [5] Market Position and Investor Relations - The company reassured investors that its operations remain normal despite stock price fluctuations, which are influenced by multiple external factors [4] - The management is committed to transparency and timely information disclosure to maintain investor trust [5] - Plans to achieve a market capitalization of CNY 100 billion are part of the company's long-term vision [5]

证券日报网讯 9月18日晚间，乐心医疗发布关于2023年限制性股票激励计划第一类限制性股票第二个解 除限售期解除限售股份上市流通的提示性公告称，公司本次解除限售的第一类限制性股票数量为100.00 万股，占公司目前总股本的0.4583%，涉及激励对象1名；本次解除限售的第一类限制性股票上市流通 日期为2025年9月23日（星期二）。 （文章来源：证券日报） ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-100 2、本次解除限售的第一类限制性股票上市流通日为 2025 年 9 月 23 日（星 期二）。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日 召开的第五届董事会第五次会议审议通过了《关于 2023 年限制性股票激励计划 第一类限制性股票第二个解除限售期解除限售条件成就的议案（调整后）》，根据 公司 2023 年限制性股票激励计划（以下简称"本激励计划"）的相关规定，近 日公司为符合条件的 1 名激励对象在中国证券登记结算有限责任公司深圳分公 司办理了第一类限制性股票解除限售业务，现将具体情况公告如下： 一、本激励计划已履行的相关审批程序 1、2023 年 7 月 26 日，公司召开第四届董事会第八次会议，审议通过了《关 于<2023 年限制性股票激励计划（草案）>及其摘要的议案》、《关于<2023 年限 制性股票激励计划实施考核管理办法>的议案》以及《关于提请股东大会授权董 事会办理公司股权激励计划相关事宜的议案》等议案，独立董事就相关事项发表 了一致同意的独立意见。同日，公司 ...

证券日报网讯 9月16日晚间，乐心医疗发布公告称，公司近日收到广东省药品监督管理局的通知，获悉 公司申报的医疗器械注册证变更注册事项已获受理以及公司控股子公司深圳市瑞康宏业科技开发有限公 司申报的医疗器械注册证延续注册事项已通过审批。 （文章来源：证券日报） ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-098 广东乐心医疗电子股份有限公司 关于公司医疗器械注册证变更注册获得受理 及控股子公司完成医疗器械注册证延续注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到广东省药品 监督管理局的通知，获悉公司申报的医疗器械注册证变更注册事项已获受理以及 公司控股子公司深圳市瑞康宏业科技开发有限公司（以下简称"瑞康宏业"）申 报的医疗器械注册证延续注册事项已通过审批，现将相关情况公告如下： 一、基本情况 二、对公司的影响 公司定位于"医疗级远程健康监测设备及服务提供商"，始终高度重视医疗 器械标准符合性，推动全系列产品向医疗级方向发展。上述医疗器械注册证的变 更系基于产品系列标准更新作出，控股子公司瑞康宏业医疗注册证的延续系基于 其业务开展的实际需要而决定的，对公司优化产品矩阵、增强产品市场竞争力均 起到积极作用，有利于公司进一步加快市场开拓、实现战略落地。 上述医疗器械注册证变更事宜目前尚处于受理阶段，后续仍需相 ...

本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。 届时公司董事长潘伟潮先生、总经理潘志刚先生、董事会秘书李薇女士、财 务总监吴蓉女士将在线就公司 2025 年半年度业绩、公司治理、发展战略、经营 状况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 广东乐心医疗电子股份有限公司 董事会 乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-099 广东乐心医疗电子股份有限公司 关于参加2025年广东辖区投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东乐心医疗电子股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会与深圳市全景网络有限 公司联合举办的"向新提质 价值领航——2025 年广东辖区投资者集体接待日 活动"，现将相关事项 ...

Group 1 - The core point of the news is the resignation of Huang Linxiang as the employee representative director and CFO of Le Xin Medical due to personal reasons, and the appointment of Wu Rong as the new CFO [1] - Le Xin Medical's revenue composition for the first half of 2025 is as follows: home medical products account for 66.29%, electronic health scales account for 24.17%, other products account for 7.55%, and wearable sports wristbands account for 1.99% [1] - As of the report date, Le Xin Medical has a market capitalization of 3.2 billion yuan [1] Group 2 - Related news includes the resignation of Yi Bingmin from Gao Le Co. as CFO and Vice General Manager [2] - Zhao Bin's resignation as Vice President and CFO of Yingxin Development is also noted [2] - Chen Feng Technology has appointed Dong Jianzao as the new CFO [2]

Core Viewpoint - The resignation of Huang Linxiang from all positions at Lexin Medical marks a significant leadership change, with Wu Rong appointed as the new CFO, indicating a shift in the company's financial management strategy [1][2]. Group 1: Personnel Changes - Huang Linxiang has resigned from all positions, including CFO, employee representative director, and committee member, effective September 9, 2025 [2]. - Huang held 95,000 shares in the company, including 40,000 restricted shares from the 2023 incentive plan, which will be repurchased and canceled by the company [2]. - Wu Rong, previously a member of the fourth supervisory board, has been appointed as the new CFO, bringing extensive experience in financial management within the company [2][3]. Group 2: Financial Performance - In the first half of 2025, Lexin Medical reported a revenue of 521 million yuan, representing a year-on-year growth of 4.57% [3]. - The net profit attributable to shareholders for the same period was 42 million yuan, showing a year-on-year increase of 21.35% [3].

Market Overview - The Shanghai Composite Index closed at 3855.10 points, above the six-month moving average, with an increase of 1.12% [1] - The total trading volume of A-shares reached 14961.95 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 118 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Xinxiangwei (688593) with a deviation rate of 18.44% and a price increase of 20.00% [1] - Fabon Information (300925) with a deviation rate of 11.71% and a price increase of 13.31% [1] - Aerospace Engineering (603698) with a deviation rate of 8.55% and a price increase of 10.01% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Huatushan (300492) with a deviation rate of 8.31% and a price increase of 10.82% [1] - Leidi Technology (300652) with a deviation rate of 6.06% and a price increase of 8.27% [1] - Tianshan Electric (301379) with a deviation rate of 4.05% and a price increase of 4.14% [1]